Abstract
Introduction: S-1 is an oral combination of tegafur (a prodrug of 5-fluorouracil (5-FU)) and two modulators of 5-FU metabolism, gimeracil and oteracil. This combination was optimized to reduce the toxicity of 5-FU due to toxic metabolites. S-1 in combination with cisplatin is approved for use in AGC in Europe since 2011. We report here post-approval safety data for 11 AGC patients treated with S-1 regimens in daily practice including combination with oxaliplatin (SOX) and trastuzumab. Data were collected in the observational Study of Compliance Observed with Oral fluoro Pyrimidine Teysuno (SCOOP).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
